BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2024, BeiGene, Ltd. (ONC) reported revenue of $1.13 billion, up 77.8% over the same period last year. EPS came in at -$1.43, compared to -$3.53 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.09 billion, representing a surprise of +3.76%. The company delivered an EPS surprise of -62.50%, with the consensus EPS estimate being -$0.88.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how BeiGene performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product revenue, net: $1.12 billion versus $1.08 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +77.3% change. Product Revenue- BRUKINSA(Zanubrutinib): $828.03 million compared to the $764.99 million average estimate based on four analysts. Product Revenue- Tislelizumab: $153.80 million compared to the $174.58 million average estimate based on four analysts. Product Revenue- REVLIMID: $3.56 million versus $10.17 million estimated by three analysts on average. Product Revenue- Other: $18.24 million compared to the $14.21 million average estimate based on three analysts. Product Revenue- XGEVA: $62.52 million versus the three-analyst average estimate of $69.93 million. Product Revenue- POBEVCY: $13.11 million versus $14.35 million estimated by three analysts on average. Product Revenue- BLINCYTO: $20.62 million versus the three-analyst average estimate of $22.40 million. Product Revenue- KYPROLIS: $18.15 million compared to the $19.37 million average estimate based on three analysts. Collaboration revenue: $9.79 million versus $6.22 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +152.1% change. View all Key Company Metrics for BeiGene here>>>Shares of BeiGene have returned +14.2% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BeiGene, Ltd. (ONC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks